MAFB MUTANTS AND USES THEREOF
Publikation: Geistiges Eigentum › Patentanmeldung/Patent
Beitragende
- INSERM - Institut national de la santé et de la recherche médicale
- European Molecular Biology Laboratory (EMBL) Heidelberg
- Centre national de la recherche scientifique (CNRS)
- Aix-Marseille Université
Abstract
The present invention relates to MafB mutants and uses thereof for research, screening and therapeutic purposes. In particular, the present invention relates to a MafB mutant polypeptide comprising the sequence as set forth in SEQ ID NO: 1 or 2 or a function conservative variant thereof wherein the glutaminic acid residue at position 269 has been deleted or substituted with a basic amino acid. The present invention also relates to a MafB mutant polypeptide comprising the sequence as set forth in SEQ ID NO: 1 or 2 or a function conservative variant thereof wherein the valine residue at position 277 has been deleted or substituted with a polar amino acid.
Details
The present invention relates to MafB mutants and uses thereof for research, screening and therapeutic purposes. In particular, the present invention relates to a MafB mutant polypeptide comprising the sequence as set forth in SEQ ID NO: 1 or 2 or a function conservative variant thereof wherein the glutaminic acid residue at position 269 has been deleted or substituted with a basic amino acid. The present invention also relates to a MafB mutant polypeptide comprising the sequence as set forth in SEQ ID NO: 1 or 2 or a function conservative variant thereof wherein the valine residue at position 277 has been deleted or substituted with a polar amino acid.
| Originalsprache | Englisch |
|---|---|
| IPC (Internationale Patentklassifikation) | C07K 14/ 82 A I |
| Veröffentlichungsnummer | WO2015082525 |
| Anmeldedatum | 3 Dez. 2014 |
| Land/Gebiet | Deutschland |
| Prioritätsdatum | 3 Dez. 2013 |
| Prioritätsnummer | EP20130306661 |
| Publikationsstatus | Veröffentlicht - 11 Juni 2015 |
| Extern publiziert | Ja |